Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine
Background: The study considered the long-term outcome of patients with papillary thyroid carcinoma treated with 30 mCi radioiodine. Objective: The aims of this study were to define and compare the remission rates of papillary thyroid carcinoma ablated with 30 mCi 131 I prepared by either thyroid ho...
Gespeichert in:
| Veröffentlicht in: | Thyroid (New York, N.Y.) N.Y.), 2016-07, Vol.26 (7), p.951-958 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 958 |
|---|---|
| container_issue | 7 |
| container_start_page | 951 |
| container_title | Thyroid (New York, N.Y.) |
| container_volume | 26 |
| creator | Mujammami, Muhammad Hier, Michael P. Payne, Richard J. Rochon, Louise Tamilia, Michael |
| description | Background:
The study considered the long-term outcome of patients with papillary thyroid carcinoma treated with 30 mCi radioiodine.
Objective:
The aims of this study were to define and compare the remission rates of papillary thyroid carcinoma ablated with 30 mCi
131
I prepared by either thyroid hormone withdrawal (THW) or recombinant human thyrotropin (rhTSH; Thyrogen
®
), and to identify variables predictive of a favorable prognosis.
Method:
An observational study was conducted at an academic medical center and a comparative summary of six studies is presented. Three hundred and seventy patients (THW group,
n
= 203; rhTSH group,
n
= 167) were recruited from a prospectively managed registry. The mean follow-up was 9.3 years (range 5.1–15.8 years) in the THW group and 7.1 years (range 5.0–9.7 years) in the rhTSH group. The primary endpoint was the long-term remission rates (no evidence of disease) in the THW group compared with the rhTH group.
Results:
The response at 12–18 months after 30 mCi remnant ablation was excellent in 79.3% and 76.0% of patients in the THW group and the rhTSH group, respectively (
p
> 0.05). The long-term remission rates also did not significantly differ between both groups at 95.6% and 97.0%. Although the surveillance period for the THW group exceeded that of the rhTSH group, no significant difference in recurrence-free survival was discerned by the Kaplan–Meier curves. In a multivariate analysis, an excellent response to therapy at 12–18 months correlated significantly with long-term remission rates in the THW group (
p
= 0.031, odds ratio [OR] = 2.6 [confidence interval (CI) 1.1–6.0]), the rhTSH group (
p
= 0.03, OR = 5.3 [CI 1.2–23.8]), and the pooled groups (
p
= 0.001, OR = 3.43 [CI 1.63–7.2]). The pre-ablation thyroglobulin level significantly correlated with remission rates only in the THW group (
p
= 0.035, OR = 5.5 [CI 1.1–27.1]).
Conclusions:
The response to remnant ablation with 30 mCi radioiodine is often excellent, and the long-term remission rates can be expected to be high, independent of the method of delivery (i.e., THW or rhTSH). |
| doi_str_mv | 10.1089/thy.2016.0036 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1802742535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1802742535</sourcerecordid><originalsourceid>FETCH-LOGICAL-c337t-2be101da67cbcacd965d3f429a0d26db2168176bbf01bb9a38deafe171c1146f3</originalsourceid><addsrcrecordid>eNqFkEtrGzEUhUVIaF5dZhu0zGacK8kz8iyDadqAISE460GPO7bCjORKGhr_-8o47TYrPfjOgfMRcsNgxmDR3uftfsaBNTMA0ZyQC1bXsmpBytNyhxoqyevmnFym9A4FW0jxjZxzyWrgIC7Ixyr4TbXGONLnKZswYqKhpy8qO_Q50T8ub8tr54ZBxT1db_cxOEuXyhuM9M1bjJvg_Ia-4uiVz_RBDyUb_DEpgI4l6pZTdKX5VVkXXLDO4zU569WQ8PvneUXeHn-sl7-q1fPPp-XDqjJCyFxxjQyYVY002ihj26a2op_zVoHljdW8TGKy0boHpnWrxMKi6pFJZhibN724InfH3l0MvydMuRtdMljmeAxT6tgCuJzzWtQFrY6oiSGliH23i24sszsG3UF2V2R3B9ndQXbhbz-rJz2i_U__s1sAcQQO38r7waHGmL-o_QtyNo29</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1802742535</pqid></control><display><type>article</type><title>Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Mujammami, Muhammad ; Hier, Michael P. ; Payne, Richard J. ; Rochon, Louise ; Tamilia, Michael</creator><creatorcontrib>Mujammami, Muhammad ; Hier, Michael P. ; Payne, Richard J. ; Rochon, Louise ; Tamilia, Michael</creatorcontrib><description>Background:
The study considered the long-term outcome of patients with papillary thyroid carcinoma treated with 30 mCi radioiodine.
Objective:
The aims of this study were to define and compare the remission rates of papillary thyroid carcinoma ablated with 30 mCi
131
I prepared by either thyroid hormone withdrawal (THW) or recombinant human thyrotropin (rhTSH; Thyrogen
®
), and to identify variables predictive of a favorable prognosis.
Method:
An observational study was conducted at an academic medical center and a comparative summary of six studies is presented. Three hundred and seventy patients (THW group,
n
= 203; rhTSH group,
n
= 167) were recruited from a prospectively managed registry. The mean follow-up was 9.3 years (range 5.1–15.8 years) in the THW group and 7.1 years (range 5.0–9.7 years) in the rhTSH group. The primary endpoint was the long-term remission rates (no evidence of disease) in the THW group compared with the rhTH group.
Results:
The response at 12–18 months after 30 mCi remnant ablation was excellent in 79.3% and 76.0% of patients in the THW group and the rhTSH group, respectively (
p
> 0.05). The long-term remission rates also did not significantly differ between both groups at 95.6% and 97.0%. Although the surveillance period for the THW group exceeded that of the rhTSH group, no significant difference in recurrence-free survival was discerned by the Kaplan–Meier curves. In a multivariate analysis, an excellent response to therapy at 12–18 months correlated significantly with long-term remission rates in the THW group (
p
= 0.031, odds ratio [OR] = 2.6 [confidence interval (CI) 1.1–6.0]), the rhTSH group (
p
= 0.03, OR = 5.3 [CI 1.2–23.8]), and the pooled groups (
p
= 0.001, OR = 3.43 [CI 1.63–7.2]). The pre-ablation thyroglobulin level significantly correlated with remission rates only in the THW group (
p
= 0.035, OR = 5.5 [CI 1.1–27.1]).
Conclusions:
The response to remnant ablation with 30 mCi radioiodine is often excellent, and the long-term remission rates can be expected to be high, independent of the method of delivery (i.e., THW or rhTSH).</description><identifier>ISSN: 1050-7256</identifier><identifier>EISSN: 1557-9077</identifier><identifier>DOI: 10.1089/thy.2016.0036</identifier><identifier>PMID: 27150203</identifier><language>eng</language><publisher>United States: Mary Ann Liebert, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Carcinoma, Papillary - diagnostic imaging ; Carcinoma, Papillary - radiotherapy ; Female ; Follow-Up Studies ; Humans ; Iodine Radioisotopes - therapeutic use ; Male ; Middle Aged ; Multivariate Analysis ; Radiotherapy, Adjuvant - methods ; Registries ; Remission Induction ; Thyroid Cancer, Papillary ; Thyroid Neoplasms - diagnostic imaging ; Thyroid Neoplasms - radiotherapy ; Thyroid Radiology and Nuclear Medicine ; Thyroidectomy ; Treatment Outcome</subject><ispartof>Thyroid (New York, N.Y.), 2016-07, Vol.26 (7), p.951-958</ispartof><rights>2016, Mary Ann Liebert, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c337t-2be101da67cbcacd965d3f429a0d26db2168176bbf01bb9a38deafe171c1146f3</citedby><cites>FETCH-LOGICAL-c337t-2be101da67cbcacd965d3f429a0d26db2168176bbf01bb9a38deafe171c1146f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27150203$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mujammami, Muhammad</creatorcontrib><creatorcontrib>Hier, Michael P.</creatorcontrib><creatorcontrib>Payne, Richard J.</creatorcontrib><creatorcontrib>Rochon, Louise</creatorcontrib><creatorcontrib>Tamilia, Michael</creatorcontrib><title>Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine</title><title>Thyroid (New York, N.Y.)</title><addtitle>Thyroid</addtitle><description>Background:
The study considered the long-term outcome of patients with papillary thyroid carcinoma treated with 30 mCi radioiodine.
Objective:
The aims of this study were to define and compare the remission rates of papillary thyroid carcinoma ablated with 30 mCi
131
I prepared by either thyroid hormone withdrawal (THW) or recombinant human thyrotropin (rhTSH; Thyrogen
®
), and to identify variables predictive of a favorable prognosis.
Method:
An observational study was conducted at an academic medical center and a comparative summary of six studies is presented. Three hundred and seventy patients (THW group,
n
= 203; rhTSH group,
n
= 167) were recruited from a prospectively managed registry. The mean follow-up was 9.3 years (range 5.1–15.8 years) in the THW group and 7.1 years (range 5.0–9.7 years) in the rhTSH group. The primary endpoint was the long-term remission rates (no evidence of disease) in the THW group compared with the rhTH group.
Results:
The response at 12–18 months after 30 mCi remnant ablation was excellent in 79.3% and 76.0% of patients in the THW group and the rhTSH group, respectively (
p
> 0.05). The long-term remission rates also did not significantly differ between both groups at 95.6% and 97.0%. Although the surveillance period for the THW group exceeded that of the rhTSH group, no significant difference in recurrence-free survival was discerned by the Kaplan–Meier curves. In a multivariate analysis, an excellent response to therapy at 12–18 months correlated significantly with long-term remission rates in the THW group (
p
= 0.031, odds ratio [OR] = 2.6 [confidence interval (CI) 1.1–6.0]), the rhTSH group (
p
= 0.03, OR = 5.3 [CI 1.2–23.8]), and the pooled groups (
p
= 0.001, OR = 3.43 [CI 1.63–7.2]). The pre-ablation thyroglobulin level significantly correlated with remission rates only in the THW group (
p
= 0.035, OR = 5.5 [CI 1.1–27.1]).
Conclusions:
The response to remnant ablation with 30 mCi radioiodine is often excellent, and the long-term remission rates can be expected to be high, independent of the method of delivery (i.e., THW or rhTSH).</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Papillary - diagnostic imaging</subject><subject>Carcinoma, Papillary - radiotherapy</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Iodine Radioisotopes - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Radiotherapy, Adjuvant - methods</subject><subject>Registries</subject><subject>Remission Induction</subject><subject>Thyroid Cancer, Papillary</subject><subject>Thyroid Neoplasms - diagnostic imaging</subject><subject>Thyroid Neoplasms - radiotherapy</subject><subject>Thyroid Radiology and Nuclear Medicine</subject><subject>Thyroidectomy</subject><subject>Treatment Outcome</subject><issn>1050-7256</issn><issn>1557-9077</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEtrGzEUhUVIaF5dZhu0zGacK8kz8iyDadqAISE460GPO7bCjORKGhr_-8o47TYrPfjOgfMRcsNgxmDR3uftfsaBNTMA0ZyQC1bXsmpBytNyhxoqyevmnFym9A4FW0jxjZxzyWrgIC7Ixyr4TbXGONLnKZswYqKhpy8qO_Q50T8ub8tr54ZBxT1db_cxOEuXyhuM9M1bjJvg_Ia-4uiVz_RBDyUb_DEpgI4l6pZTdKX5VVkXXLDO4zU569WQ8PvneUXeHn-sl7-q1fPPp-XDqjJCyFxxjQyYVY002ihj26a2op_zVoHljdW8TGKy0boHpnWrxMKi6pFJZhibN724InfH3l0MvydMuRtdMljmeAxT6tgCuJzzWtQFrY6oiSGliH23i24sszsG3UF2V2R3B9ndQXbhbz-rJz2i_U__s1sAcQQO38r7waHGmL-o_QtyNo29</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Mujammami, Muhammad</creator><creator>Hier, Michael P.</creator><creator>Payne, Richard J.</creator><creator>Rochon, Louise</creator><creator>Tamilia, Michael</creator><general>Mary Ann Liebert, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160701</creationdate><title>Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine</title><author>Mujammami, Muhammad ; Hier, Michael P. ; Payne, Richard J. ; Rochon, Louise ; Tamilia, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c337t-2be101da67cbcacd965d3f429a0d26db2168176bbf01bb9a38deafe171c1146f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Papillary - diagnostic imaging</topic><topic>Carcinoma, Papillary - radiotherapy</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Iodine Radioisotopes - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Radiotherapy, Adjuvant - methods</topic><topic>Registries</topic><topic>Remission Induction</topic><topic>Thyroid Cancer, Papillary</topic><topic>Thyroid Neoplasms - diagnostic imaging</topic><topic>Thyroid Neoplasms - radiotherapy</topic><topic>Thyroid Radiology and Nuclear Medicine</topic><topic>Thyroidectomy</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mujammami, Muhammad</creatorcontrib><creatorcontrib>Hier, Michael P.</creatorcontrib><creatorcontrib>Payne, Richard J.</creatorcontrib><creatorcontrib>Rochon, Louise</creatorcontrib><creatorcontrib>Tamilia, Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Thyroid (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mujammami, Muhammad</au><au>Hier, Michael P.</au><au>Payne, Richard J.</au><au>Rochon, Louise</au><au>Tamilia, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine</atitle><jtitle>Thyroid (New York, N.Y.)</jtitle><addtitle>Thyroid</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>26</volume><issue>7</issue><spage>951</spage><epage>958</epage><pages>951-958</pages><issn>1050-7256</issn><eissn>1557-9077</eissn><abstract>Background:
The study considered the long-term outcome of patients with papillary thyroid carcinoma treated with 30 mCi radioiodine.
Objective:
The aims of this study were to define and compare the remission rates of papillary thyroid carcinoma ablated with 30 mCi
131
I prepared by either thyroid hormone withdrawal (THW) or recombinant human thyrotropin (rhTSH; Thyrogen
®
), and to identify variables predictive of a favorable prognosis.
Method:
An observational study was conducted at an academic medical center and a comparative summary of six studies is presented. Three hundred and seventy patients (THW group,
n
= 203; rhTSH group,
n
= 167) were recruited from a prospectively managed registry. The mean follow-up was 9.3 years (range 5.1–15.8 years) in the THW group and 7.1 years (range 5.0–9.7 years) in the rhTSH group. The primary endpoint was the long-term remission rates (no evidence of disease) in the THW group compared with the rhTH group.
Results:
The response at 12–18 months after 30 mCi remnant ablation was excellent in 79.3% and 76.0% of patients in the THW group and the rhTSH group, respectively (
p
> 0.05). The long-term remission rates also did not significantly differ between both groups at 95.6% and 97.0%. Although the surveillance period for the THW group exceeded that of the rhTSH group, no significant difference in recurrence-free survival was discerned by the Kaplan–Meier curves. In a multivariate analysis, an excellent response to therapy at 12–18 months correlated significantly with long-term remission rates in the THW group (
p
= 0.031, odds ratio [OR] = 2.6 [confidence interval (CI) 1.1–6.0]), the rhTSH group (
p
= 0.03, OR = 5.3 [CI 1.2–23.8]), and the pooled groups (
p
= 0.001, OR = 3.43 [CI 1.63–7.2]). The pre-ablation thyroglobulin level significantly correlated with remission rates only in the THW group (
p
= 0.035, OR = 5.5 [CI 1.1–27.1]).
Conclusions:
The response to remnant ablation with 30 mCi radioiodine is often excellent, and the long-term remission rates can be expected to be high, independent of the method of delivery (i.e., THW or rhTSH).</abstract><cop>United States</cop><pub>Mary Ann Liebert, Inc</pub><pmid>27150203</pmid><doi>10.1089/thy.2016.0036</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1050-7256 |
| ispartof | Thyroid (New York, N.Y.), 2016-07, Vol.26 (7), p.951-958 |
| issn | 1050-7256 1557-9077 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1802742535 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Carcinoma, Papillary - diagnostic imaging Carcinoma, Papillary - radiotherapy Female Follow-Up Studies Humans Iodine Radioisotopes - therapeutic use Male Middle Aged Multivariate Analysis Radiotherapy, Adjuvant - methods Registries Remission Induction Thyroid Cancer, Papillary Thyroid Neoplasms - diagnostic imaging Thyroid Neoplasms - radiotherapy Thyroid Radiology and Nuclear Medicine Thyroidectomy Treatment Outcome |
| title | Long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 milliCuries Radioiodine |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A12%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Outcomes%20of%20Patients%20with%20Papillary%20Thyroid%20Cancer%20Undergoing%20Remnant%20Ablation%20with%2030%20milliCuries%20Radioiodine&rft.jtitle=Thyroid%20(New%20York,%20N.Y.)&rft.au=Mujammami,%20Muhammad&rft.date=2016-07-01&rft.volume=26&rft.issue=7&rft.spage=951&rft.epage=958&rft.pages=951-958&rft.issn=1050-7256&rft.eissn=1557-9077&rft_id=info:doi/10.1089/thy.2016.0036&rft_dat=%3Cproquest_cross%3E1802742535%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1802742535&rft_id=info:pmid/27150203&rfr_iscdi=true |